TELA Bio, Inc. (TELA) Form 10-Q — Aug 11, 2026
TELA Bio reported Q2 2026 revenue of $19.3 million, down 4% year over year, as OviTex PRS sales fell roughly 25% and net loss widened 13% to $11.3 million. The 10-Q discloses substantial doubt about the company's ability to continue as a going concern. Management forecasts indicate it is probable TELA will miss the minimum revenue covenant under its $70 million Perceptive Credit Agreement within twelve months, and the company does not expect sufficient liquidity to repay the $60 million outstanding if the loan is accelerated.
Key figures
- Revenue
- 19291000
- Total Debt
- 56081000
- Revenue Yoy
- -4%
- Total Assets
- 59738000
- Cash Position
- 30424000
- Shares Outstanding
- 44894757
- Maturity date
- November 14, 2030
- Gross margin q2
- 72%
- Working capital
- 36300000
- Ovi Tex q2 revenue
- 13308000
- Perceptive margin
- 7.85% plus greater of SOFR or 4.25%
- Six month revenue
- 38350000
- Accumulated deficit
- 421100000
- Interest expense q2
- 2076000
- Atm program capacity
- 50000000
- Ovi Tex PRS q2 revenue
- 5460000
- Warrants outstanding
- 14711556
- Ovi Tex unit growth q2
- 12%
- H1 operating cash burn
- 20551000
- Ovi Tex PRS unit decline q2
- -23%
- Perceptive facility total
- 70000000
- Minimum liquidity covenant
- 5000000
- Interest expense yoy growth
- 75%
- Perceptive principal outstanding
- 60000000
- Us tariff on new zealand imports
- 12.5%
- Perceptive delayed draw available
- 10000000
Price after filing
Close on the filing date to close N calendar days later (from $0.87). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.